Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction

Autor: Muhammed Salih Ateş, Canan Aydoğan, Bahadir Ozturk, Fikret Akyurek, Abdullah Tuncez, Hüseyin Tezcan, Bülent Behlül Altunkeser, Ulvi Yalçın, Emre Can Kirik, Nazif Aygul, Kenan Demir
Přispěvatelé: Selçuk Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Tunçez, Abdullah., Altunkeser, Bülent Behlül., Öztürk, Bahadır., Ateş, Muhammed Salih., Tezcan, Hüseyin., Aydoğan, Canan., Kırık, Emre Can., Yalçın, Ulvi., Aygül, Nazif., Demir, Kenan., Akyürek, Fikret.
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Male
medicine.medical_specialty
lcsh:Diseases of the circulatory (Cardiovascular) system
Galectin 3
Galectins
Atorvastatin
030204 cardiovascular system & hematology
03 medical and health sciences
0302 clinical medicine
Internal medicine
galectin-3
medicine
Humans
Chemerin
Rosuvastatin
In patient
030212 general & internal medicine
Myocardial infarction
Rosuvastatin Calcium
Original Investigation
endocan
biology
business.industry
Angioplasty
Atorvastatin 80 MG
Blood Proteins
atorvastatin
Middle Aged
medicine.disease
Pathophysiology
Neoplasm Proteins
Treatment Outcome
Endocrinology
myocardial infarction
Galectin-3
lcsh:RC666-701
biology.protein
Female
Proteoglycans
Chemokines
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cardiology and Cardiovascular Medicine
business
rosuvastatin
Biomarkers
chemerin
medicine.drug
Zdroj: Anatolian Journal of Cardiology, Vol 22, Iss 5, Pp 240-249 (2019)
Anatolian Journal of Cardiology
Popis: WOS: 000493983800007
PubMed: 31674929
Objective: Endocan, chemerin, and galectin-3 are discrete biomarkers associated with cardiovascular diseases and acting through different pathophysiological pathways. The aim of this study is to investigate and compare the effects of high doses of atorvastatin and rosuvastatin on serum endocan, chemerin, and galectin-3 levels in patients with acute myocardial infarction (AMI). Methods: Sixty-three patients with AMI were randomized to receive atorvastatin (80 mg/day) or rosuvastatin (40 mg/day) after percutaneous revascularization. Serum levels of endocan, chemerin, and galectin-3 were evaluated at baseline and after 4-week therapy. Results: Endocan levels were not decreased statistically significantly with atorvastatin 80 mg, but rosuvastatin 40 mg markedly decreased the levels of endocan according to baseline [from 110.27 (86.03-143.69) pg/mL to 99.22 (78.30-122.87) pg/mL with atorvastatin 80 mg and from 110.73 (77.28-165.22) pg/mL to 93.40 (70.48-115.13) pg/mL with rosuvastatin 40 mg, p=0.242 for atorvastatin 80 mg and p=0.014 for rosuvastatin 40 mg]. Chemerin levels significantly decreased in both groups according to baseline [from 264.90 (196.00-525.95) ng/mL to 135.00 (105.95-225.65) ng/mL with atorvastatin 80 mg and from 309.95 (168.87-701.27) ng/mL to 121.25 (86.60-212.65) ng/mL with rosuvastatin 40 mg, p
Selcuk UniversitySelcuk University
of this article presented as poster abstract at the 23rd International Congress of Clinical Chemistry and Laboratory Medicine Congress, helded at the Durban International Convention Center in Durban, South Africa on October 22-25, 2017. This study was supported by Scientific Research Project Coordinator of Selcuk University and the founding source did not involve in study design, in the collection, analysis, and interpretation of data; in the writing of the report; in the decision to submit the article for publication.
Databáze: OpenAIRE
Externí odkaz: